Search

Your search keyword '"Del Poggio, Paolo"' showing total 199 results

Search Constraints

Start Over You searched for: Author "Del Poggio, Paolo" Remove constraint Author: "Del Poggio, Paolo"
199 results on '"Del Poggio, Paolo"'

Search Results

1. THU-161 Hepatic sarcoidosis diagnosis and management: an italian multicenter study

2. THU-182 Acute liver injury with autoimmune features following SARS-CoV-2 vaccination in an ERN/IAIHG cohort: autoimmune hepatitis versus drug-induced autoimmune-like hepatitis

4. High rates of 30-day mortality in patients with cirrhosis and COVID-19

5. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C

6. Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals

7. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

8. MAFLD (metabolic associated fatty liver disease) outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct antiviral agents

9. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals

10. Histological and serological features of acute liver injury after SARS-CoV-2 vaccination

11. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals

16. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study

22. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience

23. High rates of 30-day mortality in patients with cirrhosis and COVID-19

24. THU-165 - MAFLD (metabolic associated fatty liver disease) outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct antiviral agents

25. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres

26. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study.

29. Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-naïve patients with chronic hepatitis B followed for 3 years in a multicenter European study: 401

30. Entecavir treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment: 366

31. Alphafetoprotein and Transplant Survival Benefit for Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study.: Abstract# O-122

33. Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohort

39. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C

41. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

42. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma

44. Economic Evaluation of Different Organizational Models for the Management of Patients with Hepatitis C

46. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients

48. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study

49. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma

50. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

Catalog

Books, media, physical & digital resources